Effects of Delta-9-THC and Iomazenil in Healthy Humans

Conditions

Mental Disorders | Psychotic Disorders | Schizophrenia

Trial Phase

Trial Purpose and Description

Trial Purpose

The study aims to examine the combined effects of delta-9-tetrahydrocannabinol (∆-9-THC or THC) and iomazenil on thinking, perception, mood, memory, attention, and electrical activity of the brain (EEG). THC is the active ingredient of marijuana, cannabis, "ganja", or "pot". Iomazenil is a drug that works opposite to drugs like valium. The purpose of this study is to determine whether the administration of iomazenil will alter the effects of THC.


Participation Guidelines

Age:
18 Years - 55 Years
Gender:
Male

Eligibility Criteria

Inclusion Criteria:

  • Exposed to cannabis at least once in their lifetime

Exclusion Criteria:

  • Cannabis naive
  • History of hearing deficit
Sponsor:
National Institute of Mental Health
Yale University
Dates:
04/21/2009
Last Updated:
Study HIC#:
0901004662